AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02279524 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aramchol
Description: Subjects will be administered Aramchol as follows:~* One tablet of Aramchol 400 mg and one tablet of matching placebo for Aramchol.~* One tablet of Aramchol 400 mg and one tablet of Aramchol 200 mg.~* Two tablet of Aramchol matching placebo. The tablets should be taken orally in the morning within 30 min after breakfast with a glass of water (250 ml).~Subjects are allowed to omit study drugs up to 3 consecutive days during the study.
Study NCT03509207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat Oral Capsule
Description: Vorinostat, 400 mg orally once daily for the first 14 days of a 21 day cycle Treatment will be continued for 4 cycles. Patients with a response or stable disease after 4 cycles will be continued on vorinostat therapy at the tolerated schedule and dosage until disease progression, unacceptable toxicity or patients' withdrawal of the consent. At the maximum, a total of 12 cycles will be administered over a period of 9 months.
Study NCT04676464 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ultra- sound
Description: Ultrasound assessment of quadricep muscle layer thickness QMLT within 72hrs of initial CT scan
Study NCT01043185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3355
Description: 30 mg orally in the morning and 30 mg in the evening for 1 day
Study NCT01043185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3355
Description: 90 mg orally in the morning and 90 mg in the evening for 1 day
Study NCT01043185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3355
Description: 120 mg orally in the morning and 120 mg in the evening for 1 day
Study NCT01043185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3355
Description: 240 mg orally in the morning and 240 mg in the evening for 1 day
Study NCT01043185 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo capsules orally in the morning and placebo capsules in the evening for 1 day
Study NCT02891798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine + CBD (clonidine, buprenorphine, dexamethasone)
Description: Nerve blocks before surgery of L2-L4 and L4-S3 for Knee replacements Nerve blocks before surgery of L2-L4 for hip replacements
Study NCT02891798 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Only (control arm)
Description: Nerve blocks before surgery of L2-L4 and L4-S3 for Knee replacements Nerve blocks before surgery of L2-L4 for hip replacements
Study NCT04389749 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPM
Description: CPM-continuous passive motion device.
Study NCT03033849 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood glucose monitoring system for self-testing Contour® Next One
Description: This is a user performance study, that is intended to show whether people with diabetes are able to obtain accurate measurement results with a blood glucose monitoring system (BGMS).~The subjects' measurement technique (e.g. applying blood onto the system reagent, reading the result) will be observed and documented by study personnel.~Immediately after the measurement by the subject, the study personnel will perform a measurement with the same test meter.~Measurement results obtained by the subjects with the BGMS will be compared to measurement results obtained with the comparison method.~Sample collection for the comparison measurement will be performed by study personnel within 5 min after the subject's measurement with the test meter.~The samples will be collected from the subjects' skin puncture (if possible), an additional skin puncture (if required) will be documented.~An additional skin puncture will be performed by study personnel with single-use lancing devices.
Study NCT03033849 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood glucose monitoring system for self-testing Accu-Chek® Aviva Connect
Study NCT03033849 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood glucose monitoring system for self-testing FreeStyle Freedom Lite
Study NCT03033849 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood glucose monitoring system for self-testing OneTouch® Verio
Study NCT03033849 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood glucose monitoring system for self-testing GlucoMen® areo
Study NCT01570400 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-administered cognitive behavioral therapy (iCBT)
Description: Established form of internet-administered cognitive behavioral therapy. Controlled progress, self-help modules with psychoeducative texts, assignments and homework. Therapist assisted.
Study NCT01570400 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive bias modification training program variant 1
Description: Computerized, internet-based training program for implicit modification of cognitive bias of attention, variant 4. Participant is exposed to a pair of words or a pair of faces -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (\< or >) in the previous position of ONE of these words or faces and is then asked to press the corresponding arrow button on a keyboard. A total of 96 word pairs and 96 face pairs are shown during a session. One third is neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe always follows the more negative word or face.~Duration: approx. 10 min. per session. Frequency: Once every day for 2 weeks.
Study NCT01570400 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive bias modification training program variant 2
Description: Computerized, internet-based control training program, variant 2. Participant is exposed to a pair of words or a pair of faces -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (\< or >) in the previous position of ONE of these words or faces and is then asked to press the corresponding arrow button on a keyboard. A total of 96 word pairs and 96 face pairs are shown during a session. One third is neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe follows the more positive stimulus and the more negative stimulus with equal frequency.~Duration: approx. 10 min. per session. Frequency: Once every day for 2 weeks.
Study NCT01838174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACTHAR Gel (ACTH)
Description: 15 days of daily injections
Study NCT01838174 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV methylprednisolone (steroids)
Description: 3 days of intravenous methylprednisolone followed by 11 days of oral taper
Study NCT02590445 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: deep brain stimulation system
Study NCT02590445 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: deep brain stimulation system
Study NCT01158833 — intervention group
Intervention type: OTHER
Intervention: classification of gait in diplegic children with CP
Description: To determine the criterion validity of the classification of the pattern of diplegic gait proposed by Ferrari et al. we correlated gait patterns with the score of the FMS.
Study NCT01520415 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 2ml per injection up to a maximum of 8ml (4 identified trigger points) per visit
Study NCT01520415 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 2ml per injection up to a maximum of 8ml (4 identified trigger points) per visit
Study NCT03009539 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eHealth Familias Unidas Primary Care
Description: The experimental condition will consist of eHealth Familias Unidas Primary Care. eHealth Familias Unidas Primary Care is an adaptation of the face-to-face version of Familias Unidas. As with face-to-face Familias Unidas, eHealth Familias Unidas Primary Care aims to prevent drug use, sexual risk behaviors, and STIs by improving family functioning. Similar to face-to-face Familias Unidas, eHealth Familias Unidas is a multi-level intervention that targets risk and protective factors at the multiple systems affecting the youth and youths' family.
Study NCT02892370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR0302
Description: SHR0302 tablets (10 mg)
Study NCT00970398 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Infant formula supplemented with bovine milk Osteopontin
Description: Infant formula supplemented with bovine milk osteopontin at 50% and 100% levels of that of breast milk respectively.
Study NCT00970398 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard infant formula
Description: Infant formula without supplementation of bovine milk Osteopontin
Study NCT01862003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8931
Description: 160 mg AZD8931 tablets, twice daily on days 1 - 4 of each 2-weekly cycle
Study NCT01862003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 180 mg/m2 (IV infusion) of Irinotecan on day 1 of each 2-weekly cycle - can be given simultaneously with Folinic acid.
Study NCT01862003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folinic Acid
Description: 350 mg (IV infusion) of Folinic acid on day 1 of each 2-weekly cycle - can be given simultaneously with Irinotecan.
Study NCT02309164 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: 10 acupuncture sessions of 30 minutes each, twice a week
Study NCT02309164 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Orientation group
Description: medical management guidelines for foot / hands care, sensory desensitization, risk prevention guidelines, proper ergonomics and orthoses when necessary.
Study NCT02309164 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Orientation group
Description: medical management guidelines for foot / hands care, sensory desensitization, risk prevention guidelines, proper ergonomics and orthoses when necessary.
Study NCT03151148 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TMT Lotion
Description: TMT product and Vegetable glycerin-Cetaphil®
Study NCT03151148 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Lotion
Description: Cetaphil® moisturizing lotion and vegetable glycerin
Study NCT01628016 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: a word dot-probe task for training procedure
Description: In the word dot-probe task for training procedure of attention bias modification, 90% of the targets appeared at the neutral word position and 10% at the sad word position.In the placebo condition, the targets appeared with equal probability in the sad (50%) and neutral (50%) word positions.All participants in ABM and placebo conditions received eight 12-min training sessions over a 2-week period.During each session, participants completed 216 word dot-probe trials.
Study NCT05010057 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (PLA)
Description: Placebo capsules containing microcrystalline cellulose
Study NCT01613300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: Ofatumumab as part of the reduced intensity conditioning regimen (RIC)
Study NCT02721160 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition PBF
Description: Nutrition PBF focuses on children under five years old. It follows the standard PBF model in Burundi and combines quantitative indicators to encourage an increase in service delivery (see Table below) and qualitative indicators. Quality of nutrition activities is assessed quarterly, and a bonus or penalty is applied to subsidies received by the facilities according to their quality score.~Table: Incentivized indicators~CHW level~* nb of cases screened and referred to HC for acute malnutrition (AM)~* nb of classes promoting good nutrition~HC level~* nb of cases screened and cared for severe and moderate AM~* nb of growth follow-ups~Hospital level~* nb of treated severe AM cases with complications~* length of the stay~All hospitals with nutrition services fall under the Nutrition PBF program. At lower levels, only HCs in the intervention group and the CHW that refer to them are subject to the Nutrition PBF.
Study NCT04755790 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Point Digit
Description: Patient is fit with Point Digit partial hand prosthetic system
Study NCT02542904 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: mesenteric excision
Study NCT01862003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: 400 mg/m2 (IV bolus) of Fluorouracil on day 1 of each 2-weekly cycle, to be given after completion of Irinotecan and Folinic acid.
Study NCT01862003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: 2400 mg/m2 (IV) continuous infusion of Fluorouracil given over 46 hours - infusion to start after 5FU bolus.
Study NCT00590317 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prochlorperazine
Description: Patients receiving Prochlorperazine
Study NCT00590317 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: Patients receiving Ondansetron
Study NCT01628016 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: a word dot-probe task for training procedure
Description: In the word dot-probe task for training procedure of attention bias modification, 90% of the targets appeared at the neutral word position and 10% at the sad word position.In the placebo condition, the targets appeared with equal probability in the sad (50%) and neutral (50%) word positions.All participants in ABM and placebo conditions received eight 12-min training sessions over a 2-week period.During each session, participants completed 216 word dot-probe trials.
Study NCT04550793 — intervention group
Intervention type: DRUG
Intervention: Botulinum toxin injection
Description: Botulinum toxin injection at affected brachialis and/or biceps brachials.
Study NCT01976819 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TW speaking valve/HME
Description: The TW speaking valve with HME will be used during the day, whereas during sleep patients will use an HME without an automatic speaking valve. Data from TW15 and TW22 will be combined.
Study NCT01986218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986115
Study NCT02155374 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary advice
Description: Dietary advice to avoid food products with high glycemic index / high glucose load
Study NCT02155374 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary advice
Description: Dietary advice to avoid food products with high glycemic index / high glucose load
Study NCT06552442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: High-dose intracoronary glucocorticoid methylprednisolone to abrogate no-reflow: a unique study for restoration of infarct-related artery patency and reduction of ischemia-reperfusion injury
Study NCT01446952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin E δ-Tocotrienol
Description: The first cohort will be dosed with δ-tocotrienol at 200 mg. A minimum of 3 participants is planned for each dosing cohort with Vitamin E δ-Tocotrienol dose escalation dependent on safety from prior cohorts.
Study NCT04502810 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: High-level laser therapy
Description: Nd:Yag 1064 nm pulsed high-level Laser will be applied to the vulvar area.
Study NCT04502810 — intervention group
Intervention type: RADIATION
Group type: SHAM_COMPARATOR
Intervention: High-level laser therapy
Description: Nd:Yag 1064 nm pulsed high-level Laser will be applied to the vulvar area.
Study NCT02096861 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CT-P13
Description: CT-P13 (5 mg/kg) by intravenous (IV) infusion administered as a 2 hour IV infusion per dose
Study NCT02096861 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CT-P13
Description: CT-P13 (5 mg/kg) by intravenous (IV) infusion administered as a 2 hour IV infusion per dose
Study NCT02096861 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Remicade
Description: Remicade (5 mg/kg) by intravenous (IV) infusion administered as a 2 hour IV infusion per dose
Study NCT02096861 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Remicade
Description: Remicade (5 mg/kg) by intravenous (IV) infusion administered as a 2 hour IV infusion per dose
Study NCT02155374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucose lowering medication
Description: Regular glucose lowering medication as prescribed by the patient's own physician before study entry
Study NCT02155374 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucose lowering medication
Description: Regular glucose lowering medication as prescribed by the patient's own physician before study entry
Study NCT02155374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Chemotherapy (containing glucocorticoids) as prescribed by the patient's own physician
Study NCT02155374 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Chemotherapy (containing glucocorticoids) as prescribed by the patient's own physician
Study NCT04540055 — intervention group
Intervention type: PROCEDURE
Intervention: Paravertebral block
Description: The subjects in this group received general anesthesia and USG-guided paravertebral block
Study NCT04540055 — intervention group
Intervention type: PROCEDURE
Intervention: General Anesthesia
Description: The subjects in this group underwent MRM under routine general anesthesia without peripheral nerve block supplementation.
Study NCT02898103 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous peripheral nerve stimulation
Description: Active electrical stimulation for 5 minutes in the recovery room
Study NCT02898103 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous peripheral nerve stimulation
Description: Active electrical stimulation for 5 minutes in the recovery room
Study NCT02898103 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham stimulation
Description: Sham (placebo) stimulation for 5 minutes in the recovery room
Study NCT02898103 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham stimulation
Description: Sham (placebo) stimulation for 5 minutes in the recovery room
Study NCT02898103 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous peripheral nerve stimulation
Description: Active electrical stimulation for 2-4 weeks at home
Study NCT02898103 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous peripheral nerve stimulation
Description: Active electrical stimulation for 2-4 weeks at home
Study NCT03988517 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: timing of receiving the drug
Description: each group took levothyroxine in different timing
Study NCT04733209 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TENS, US, exercise
Description: Physiotherapy
Study NCT04733209 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TENS, US, exercise
Description: Physiotherapy
Study NCT02382367 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Blood tests (Alpha-1 antitrypsin protein measurement, elastase-inhibitory capacity of plasma measurement, phenotypic and genotypic studies)
Study NCT02488031 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Error-reduction
Description: During this time participants will use a novel, custom designed computer interface to perform goal-directed movements with each leg in a 3D virtual environment designed to emphasize accurate movements. Leg movement will be detected using the LeapMotion sensor and we will quantify time endpoint errors by comparing the timing of the foot trajectory and the required time to target.~The error-reduction intervention will be a 4-week home-based program. Each participant will train 4 days a week for approximately 1 hours per day. Within a week, the task difficulty will increase by changing the presentation of the targets to be more unpredictable and by increasing movement speed.
Study NCT02488031 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: International Cooperative Ataxia Rating Scale
Description: The ICARS is an assessment of the ataxia severity. The ICARS score is the total sum of the sub scores on specific movements and ranges from 0 to 100, with a score of 100 being indicative of the most severely affected outcome.
Study NCT02488031 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Scale for the Assessment and Rating of Ataxia
Description: The SARA is an assessment of the ataxia severity. The SARA score is the total sum of the sub scores on specific movements and ranges from 0 to 100, with a score of 100 being indicative of the most severely affected outcome.
Study NCT02488031 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Beck Depression Inventory, 2nd Ed
Description: This is a 21 question self-report inventory for measuring severity of depression.
Study NCT00312286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 851B
Description: 851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
Study NCT02488031 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stroop
Description: This test measures selective attention and cognitive flexibility through reading aloud of color names or color of the print.